

Chul-Won Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3847717/publications.pdf>

Version: 2024-02-01

168
papers

2,666
citations

236833

25
h-index

233338

45
g-index

169
all docs

169
docs citations

169
times ranked

3876
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	5.1	285
2	Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2010, 102, 209-214.	0.8	128
3	Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. <i>Blood</i> , 2011, 117, 1958-1965.	0.6	121
4	Effects of 5-Fluorouracil and Leucovorin in the Treatment of Pancreatic Biliary Tract Adenocarcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 425-428.	0.6	110
5	Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). <i>BMC Cancer</i> , 2011, 11, 321.	1.1	107
6	Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. <i>Annals of Oncology</i> , 2007, 18, 1382-1387.	0.6	90
7	Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. <i>BMC Cancer</i> , 2010, 10, 321.	1.1	73
8	A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. <i>Haematologica</i> , 2011, 96, 1441-1447.	1.7	58
9	Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 7180-7188.	3.2	57
10	Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. <i>Haematologica</i> , 2014, 99, 1191-1196.	1.7	55
11	Pulmonary marginal zone B-cell lymphoma of MALT type: What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Annals of Hematology</i> , 2010, 89, 563-568.	0.8	54
12	Serum Vascular Endothelial Growth Factor per Platelet Count in Hepatocellular Carcinoma: Correlations with Clinical Parameters and Survival. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 184-190.	0.6	53
13	Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, 235-243.	2.3	47
14	Prevalence and characteristics of anemia in the elderly: Cross-sectional study of three urban Korean population samples. <i>American Journal of Hematology</i> , 2004, 77, 26-30.	2.0	42
15	Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. <i>Leukemia and Lymphoma</i> , 2006, 47, 1265-1273.	0.6	42
16	Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports. <i>Korean Journal of Radiology</i> , 2014, 15, 494.	1.5	42
17	Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14088-14093.	3.3	37
18	Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. <i>American Journal of Hematology</i> , 2001, 66, 197-202.	2.0	35

#	ARTICLE	IF	CITATIONS
19	Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. <i>American Journal of Hematology</i> , 2003, 73, 263-266.	2.0	35
20	Increased Serum 90K and Galectin-3 Expression Are Associated with Advanced Stage and a Worse Prognosis in Diffuse Large B-Cell Lymphomas. <i>Acta Haematologica</i> , 2008, 120, 211-216.	0.7	35
21	Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. <i>European Journal of Haematology</i> , 2008, 81, 177-184.	1.1	30
22	Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 352.	0.7	27
23	uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. <i>Cell Research</i> , 2006, 16, 75-81.	5.7	26
24	Human Feeder Cells Can Support the Undifferentiated Growth of Human and Mouse Embryonic Stem Cells Using Their Own Basic Fibroblast Growth Factors. <i>Stem Cells and Development</i> , 2011, 20, 1901-1910.	1.1	26
25	Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. <i>Annals of Hematology</i> , 2011, 90, 539-546.	0.8	26
26	Long-Term Engraftment Stability of Peripheral Blood Stem Cells Cryopreserved Using the Dump-Freezing Method in a -80°C Mechanical Freezer with 10% Dimethyl Sulfoxide. <i>International Journal of Hematology</i> , 2001, 73, 245-250.	0.7	25
27	The Oral Iron Chelator Deferasirox Induces Apoptosis in Myeloid Leukemia Cells by Targeting Caspase. <i>Acta Haematologica</i> , 2011, 126, 241-245.	0.7	25
28	Recent insights regarding the molecular basis of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1-11.	0.7	25
29	The cutoff value of serum ferritin for the diagnosis of iron deficiency in community-residing older persons. <i>Annals of Hematology</i> , 2005, 84, 358-361.	0.8	24
30	The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. <i>Leukemia Research</i> , 2010, 34, 294-300.	0.4	24
31	Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. <i>Leukemia Research</i> , 2010, 34, 1175-1179.	0.4	24
32	Follow-up Study of Peripheral Blood Carcinoembryonic Antigen mRNA Using Reverse Transcription-Polymerase Chain Reaction as an Early Marker of Clinical Recurrence in Patients With Curatively Resected Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 24-29.	0.6	23
33	ANUP98-HOXD13 Fusion Gene Impairs Differentiation of B and T Lymphocytes and Leads to Expansion of Thymocytes with Partial TCRB Gene Rearrangement. <i>Journal of Immunology</i> , 2009, 183, 6227-6235.	0.4	23
34	Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. <i>British Journal of Haematology</i> , 2006, 134, 45-53.	1.2	22
35	Reduced Dose of Imatinib for Patients with Chronic Myeloid Leukemia and Low Body Surface Area. <i>Acta Haematologica</i> , 2007, 118, 219-221.	0.7	22
36	Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome. <i>Haematologica</i> , 2008, 93, 1394-1397.	1.7	22

#	ARTICLE	IF	CITATIONS
37	Guidelines for the management of myeloproliferative neoplasms. Korean Journal of Internal Medicine, 2015, 30, 771-788.	0.7	22
38	Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. Annals of Hematology, 2016, 95, 337-344.	0.8	22
39	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. Leukemia and Lymphoma, 2009, 50, 1119-1125.	0.6	21
40	Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). British Journal of Haematology, 2020, 189, 303-312.	1.2	21
41	Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma. Radiation Oncology Journal, 2015, 33, 233.	0.7	21
42	Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2006, 57, 436-442.	1.1	19
43	The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker. Anticancer Research, 2018, 38, 3935-3942.	0.5	19
44	Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. Korean Journal of Internal Medicine, 2017, 32, 711-721.	0.7	19
45	Hematopoietic Differentiation of Embryoid Bodies Derived from the Human Embryonic Stem Cell Line SNUhES3 in Co-culture with Human Bone Marrow Stromal Cells. Yonsei Medical Journal, 2005, 46, 693.	0.9	18
46	Telomere Length Shortening of Peripheral Blood Mononuclear Cells in Solid-Cancer Patients Undergoing Standard-Dose Chemotherapy Might Be Correlated with Good Treatment Response and Neutropenia Severity. Acta Haematologica, 2007, 118, 30-37.	0.7	17
47	A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. Oncotarget, 2015, 6, 44985-44994.	0.8	17
48	Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases. Acta Haematologica, 2010, 124, 92-97.	0.7	16
49	Effects of oral iron chelator deferasirox on human malignant lymphoma cells. The Korean Journal of Hematology, 2012, 47, 194.	0.7	16
50	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget, 2017, 8, 79517-79526.	0.8	16
51	Autocrine Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2 Growth Pathway Represents a Cyclooxygenase-2-Independent Target for the Cyclooxygenase-2 Inhibitor NS-398 in Colon Cancer Cells. Oncology, 2005, 68, 204-211.	0.9	15
52	Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Annals of Hematology, 2015, 94, 1485-1492.	0.8	15
53	ESHAP Salvage Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma. Journal of Korean Medical Science, 2002, 17, 621.	1.1	14
54	Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report. American Journal of Hematology, 2004, 77, 366-369.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 433-439.	1.1	14
56	Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. <i>International Journal of Hematology</i> , 2010, 92, 510-517.	0.7	13
57	Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 31-37.	1.0	13
58	Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer. <i>Cancer Research and Treatment</i> , 2014, 46, 317-321.	1.3	13
59	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018, 140, 146-156.	0.7	13
60	Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. <i>Scientific Reports</i> , 2020, 10, 39.	1.6	13
61	The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 45-62.	0.7	13
62	The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. <i>Cancer</i> , 2005, 103, 2338-2343.	2.0	12
63	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	0.5	11
64	Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment. <i>Blood</i> , 2013, 122, 1596-1596.	0.6	11
65	Relapsed or refractory nongastric marginal zone B cell lymphoma: Multicenter retrospective analysis of 92 cases. <i>American Journal of Hematology</i> , 2009, 84, 826-829.	2.0	10
66	Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein. <i>Journal of Vascular Access</i> , 2017, 18, 345-351.	0.5	10
67	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 92-95.	0.6	10
68	BK virus encephalitis without concurrent hemorrhagic cystitis in an allogeneic hematopoietic stem cell transplant recipient. <i>Blood Research</i> , 2013, 48, 226.	0.5	9
69	Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2019, 34, 579-588.	0.7	9
70	Hereditary platelet function disorder from <i>RASGRP2</i> gene mutations encoding CalDAG-GEFI identified by whole-exome sequencing in a Korean woman with severe bleeding. <i>Haematologica</i> , 2019, 104, e274-e276.	1.7	9
71	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP164). <i>TJ ETQq1 1 0.784314 9gBT /Over</i>	0.7	9
72	Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S196-S206.	0.7	9

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial. <i>Blood</i> , 2015, 126, 476-476.	0.6	9
74	Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 357-366.	0.7	9
75	A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2012, 44, 127-132.	1.3	9
76	Incidence of anemia in older Koreans: Community-based cohort study. <i>Archives of Gerontology and Geriatrics</i> , 2005, 41, 303-309.	1.4	8
77	Acute arthritis of carpal bones secondary to metastatic gastric cancer. <i>Clinical Rheumatology</i> , 2006, 25, 258-261.	1.0	8
78	Stage IV marginal zone B-cell lymphoma: prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Cancer Science</i> , 2010, 101, 2443-2447.	1.7	8
79	Selection of Elderly Acute Myeloid Leukemia Patients for Intensive Chemotherapy: Effectiveness of Intensive Chemotherapy and Subgroup Analysis. <i>Acta Haematologica</i> , 2015, 133, 300-309.	0.7	8
80	Persistent Anemia in a Patient with Diffuse Large B Cell Lymphoma: Pure Red Cell Aplasia Associated with Latent Epstein-Barr Virus Infection in Bone Marrow. <i>Journal of Korean Medical Science</i> , 2007, 22, S167.	1.1	7
81	Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim. <i>Cancer Medicine</i> , 2020, 9, 6102-6110.	1.3	7
82	First-Line Dasatinib Plus Conventional Chemotherapy in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Interim Analysis of the Korean Prospective Phase II Study. <i>Blood</i> , 2011, 118, 1516-1516.	0.6	7
83	Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 722-730.	0.7	7
84	The role of platelet function analyzer-200 in predicting perioperative bleeding risk. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1199-1209.	0.7	7
85	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea. <i>Blood</i> , 2009, 114, 5024-5024.	0.6	7
86	NK/T-Cell Lymphoma Associated with Epstein-Barr Virus in a Patient Infected with Human Immunodeficiency Virus: An Autopsy Case. <i>International Journal of Hematology</i> , 2004, 79, 480-483.	0.7	6
87	Cytogenetic abnormality involving 8p11.2 in T-lymphoblastic lymphoma: report of a new case. <i>Cancer Genetics and Cytogenetics</i> , 2009, 191, 57-58.	1.0	6
88	Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies. <i>Leukemia Research</i> , 2017, 57, 1-8.	0.4	6
89	High-Dose Cytarabine Consolidation (â‰¥1.5 g/m ²) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m ²) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen. <i>Blood</i> , 2013, 122, 2692-2692.	0.6	6
90	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia. Korean Journal of Internal Medicine, 2020, 35, 970-978.	0.7	6
92	A NUP98-HOXD13 Fusion Gene Impairs Differentiation of T and B Lymphocytes.. Blood, 2007, 110, 2650-2650.	0.6	6
93	Mesenchymal Stem Cells Derived from Human Chorionic Plate May Promote Hematopoietic Differentiation of the Human Embryonic Stem Cell Line SNUhES3. Acta Haematologica, 2006, 116, 219-222.	0.7	5
94	Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma. Acta Haematologica, 2011, 126, 79-86.	0.7	5
95	Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). International Journal of Hematology, 2012, 96, 631-637.	0.7	5
96	A Rare Case of Polycythemia Vera Following Acute Undifferentiated Leukemia Remission. Annals of Laboratory Medicine, 2014, 34, 469-470.	1.2	5
97	Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage. Acta Haematologica, 2015, 134, 59-68.	0.7	5
98	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 656-664.	0.2	5
99	Successful control of steroid-intolerant Evans' syndrome associated with allogeneic peripheral blood hematopoietic stem cell transplant by rituximab. Leukemia and Lymphoma, 2011, 52, 528-530.	0.6	4
100	The Feasibility of High-Dose Dexamethasone (HD-DEX) in Idiopathic Thrombocytopenic Purpura (ITP) in Adults; a Multi-Center Study in Korea.. Blood, 2005, 106, 4009-4009.	0.6	4
101	Unusual Presentation of Thymic Carcinoma : Hypertrophic Osteoarthropathy. Korean Journal of Internal Medicine, 2003, 18, 125-128.	0.7	3
102	Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. Medical Oncology, 2007, 24, 33-37.	1.2	3
103	Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NF- κ B and Bcl-XL. Investigational New Drugs, 2008, 26, 277-282.	1.2	3
104	The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteria. Blood Research, 2014, 49, 211.	0.5	3
105	Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. Annals of Hematology, 2014, 93, 1571-1577.	0.8	3
106	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. Transplant International, 2020, 33, 1211-1219.	0.8	3
107	Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. Korean Journal of Internal Medicine, 2021, 36, 1261-1280.	0.7	3
108	A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. Scientific Reports, 2021, 11, 18449.	1.6	3

#	ARTICLE	IF	CITATIONS
109	Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1333-1346.	0.7	3
110	Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFR α rearrangement: full recovery with low dose imatinib. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 642-644.	0.7	3
111	Composite follicular lymphoma and classic Hodgkin lymphoma. <i>Journal of Pathology and Translational Medicine</i> , 2022, 56, 57-60.	0.4	3
112	Prevalence of Iron Deficiency Anemia in Community-Dwelling Older Persons as Measured by the Transferrin Receptor-Ferritin Index. <i>Acta Haematologica</i> , 2005, 114, 180-182.	0.7	2
113	Quality assurance for a multicenter Phase II study of stereotactic ablative radiotherapy for hepatocellular carcinoma \leq 5 cm: a planning dummy run. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 535-542.	0.6	2
114	Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2019, 186, e151-e155.	1.2	2
115	Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096688.	1.1	2
116	Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab. <i>Annals of Hematology</i> , 2020, 99, 1493-1503.	0.8	2
117	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	1.0	2
118	Prognostic Significance of Ki-67 Expression in Extranodal NK/T Cell Lymphoma, Nasal Type: A Proposed Prognostic Index, KLABS Index. <i>Blood</i> , 2006, 108, 2055-2055.	0.6	2
119	Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. <i>PLoS ONE</i> , 2018, 13, e0192656.	1.1	2
120	How myeloproliferative neoplasms patients' experience and expectations differ from physicians': the international MPN Landmark survey. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 444-454.	0.7	2
121	Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia. <i>Acta Haematologica</i> , 2021, 144, 337-344.	0.7	1
122	Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. <i>American Journal of Hematology</i> , 2001, 66, 197-202.	2.0	1
123	Detection of Extracellular Protein Kinase A (ECPKA) Autoantibody in Non-Hodgkin's Lymphoma: Its Increased Antibody Titer Decreases with a Favorable Treatment Response. <i>Blood</i> , 2006, 108, 4621-4621.	0.6	1
124	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP). <i>Blood</i> , 2009, 114, 1792-1792.	0.6	1
125	Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Blood</i> , 2010, 116, 1790-1790.	0.6	1
126	Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 1687-1687.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Prevalence of and Factors Associated with Malignancy in Males with Iron-Deficiency Anemia. Korean Journal of Medicine, 2014, 87, 53.	0.1	1
128	Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. Blood, 2013, 122, 3720-3720.	0.6	1
129	Advances in the Diagnosis of Myeloproliferative Neoplasms. Korean Journal of Medicine, 2016, 90, 281-287.	0.1	1
130	Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab. Blood, 2019, 134, 2227-2227.	0.6	1
131	Postoperative Thromboembolism According to the Type of Surgery: A Nationwide Study in the Republic of Korea. Journal of Clinical Medicine, 2022, 11, 1477.	1.0	1
132	A novel cytogenetic abnormality in primary myelofibrosis. Cancer Genetics and Cytogenetics, 2009, 194, 65-66.	1.0	0
133	Endovascular Management of Symptomatic Carotid Artery Stenosis in a Patient with Thrombocytopenia. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2013, 74, e62-e65.	0.4	0
134	Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas. Japanese Journal of Clinical Oncology, 2015, 45, 914-920.	0.6	0
135	Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients. Frontiers in Oncology, 2021, 11, 687361.	1.3	0
136	The healing effect of rhGM-CSF on uninfected wounds. Immune Network, 2001, 1, 32.	1.6	0
137	Autologous Peripheral Blood Stem Cell Transplantation Using G-CSF Combined Conditioning in AML Patients. Immune Network, 2002, 2, 49.	1.6	0
138	The Cutoff Value of Serum Ferritin for the Diagnosis of Iron Deficiency in the Community-Residing Older Persons.. Blood, 2004, 104, 5291-5291.	0.6	0
139	The Effect of Telomerase Antisense for the Differentiation of Embryonic Stem Cells to Hemopoietic Stem Cells.. Blood, 2004, 104, 4201-4201.	0.6	0
140	Prediction of Survival in Patients with Non-Hodgkin's Lymphoma: Role of Tumor Necrosis Factor Ligand-Receptor and Extracellular Protein Kinase A.. Blood, 2005, 106, 4737-4737.	0.6	0
141	Treatment Outcome of Localized Extranodal NK/T Cell Lymphoma in Nasal and Upper Aerodigestive Tract: A Single Institute Experience in Korea.. Blood, 2005, 106, 2682-2682.	0.6	0
142	Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease. The Korean Journal of Hematology, 2007, 42, 335.	0.7	0
143	Serum B-Cell Activating Factor (BAFF) in Diffuse Large B-Cell Lymphoma: Its Prognostic Significance in the Rituximab Era.. Blood, 2007, 110, 1575-1575.	0.6	0
144	Reversible Posterior Leukoencephalopathy Syndrome in a Patient with Relapsed Hodgkin's Disease: A Case Report. The Korean Journal of Hematology, 2009, 44, 177.	0.7	0

#	ARTICLE	IF	CITATIONS
145	Changes in Serum Protein Profiles During Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT): Clinical Significance of Serum C-Reactive Protein and Haptoglobin Levels.. Blood, 2009, 114, 4658-4658.	0.6	0
146	Clinical Features and Prognostic Relevance of Ovarian Involvement in Non-Hodgkin's Lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) Report.. Blood, 2009, 114, 4999-4999.	0.6	0
147	Effects of Reduced Dose of Imatinib to Korean Chronic Myeloid Leukemia in Chronic Phase.. Blood, 2009, 114, 4290-4290.	0.6	0
148	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. Blood, 2009, 114, 4661-4661.	0.6	0
149	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. Blood, 2009, 114, 5017-5017.	0.6	0
150	Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).. Blood, 2009, 114, 4992-4992.	0.6	0
151	Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.. Blood, 2010, 116, 1786-1786.	0.6	0
152	Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?. Blood, 2010, 116, 5084-5084.	0.6	0
153	Pretreatment Serum Level of 15-KDa Granulysin Might Predict Recurrence and Survival of Diffuse Large B Cell Lymphoma Patients Treated by R-CHOP Regimen. Blood, 2010, 116, 1993-1993.	0.6	0
154	Treatment Outcomes and Prognostic Factors of Ifosfamide, Etoposide, Cytarabine, Methotrexate, and Dexamethasone (IVAMdex) Regimen As 3rd Line (2nd salvage) Chemotherapy in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma. Blood, 2011, 118, 2685-2685.	0.6	0
155	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. Blood, 2011, 118, 1866-1866.	0.6	0
156	Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in Korea. Blood, 2011, 118, 2021-2021.	0.6	0
157	Hepatic and Small Bowel Mucormycosis after Chemotherapy in a Patient with Acute Myeloid Leukemia: A Case Report and Literature Review. Infection and Chemotherapy, 2012, 44, 516.	1.0	0
158	Management of Polycythemia Vera and Essential Thrombocythemia. Korean Journal of Medicine, 2014, 86, 26.	0.1	0
159	Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. Blood, 2014, 124, 5151-5151.	0.6	0
160	Novel Agents in the Treatment of Chronic Lymphocytic Leukemia. Korean Journal of Medicine, 2015, 88, 258.	0.1	0
161	Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib. Blood, 2015, 126, 4053-4053.	0.6	0
162	Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies. Blood, 2015, 126, 4889-4889.	0.6	0

#	ARTICLE	IF	CITATIONS
163	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	0.6	0
164	Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy. <i>Blood</i> , 2016, 128, 3041-3041.	0.6	0
165	A Case of Acquired Factor V Deficiency after Percutaneous Coronary Intervention. <i>Korean Journal of Medicine</i> , 2017, 92, 480-483.	0.1	0
166	One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea. <i>Blood</i> , 2018, 132, 3347-3347.	0.6	0
167	The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1459-1470.	0.7	0
168	Peripheral T cell lymphoma of the nasopharynx with expansion of EBV-positive B cells masquerading as an extranodal NK/T cell lymphoma, nasal type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , 1.	1.4	0